Alzheimer's drug trial pulled before it even started
NCT ID NCT02467413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test a drug called BAC in people with Alzheimer's disease or vascular dementia. The goal was to see if it could improve thinking and memory, and to check for side effects. However, the trial was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Expected to start
-
Jan 2017
An estimate. Start dates often move.
- Expected to finish
-
Nov 2018
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: A patient is eligible for the study if all of the following apply: 1. With either gender aged at least 40 years old 2. With a diagnosis of one of the following disease i. Vascular dementia according to the NINDS-AIREN International Workshop criteria or ii. Alzheimer's disease according to the NIAAA criteria iii. "Mixed" dementia (possible Alzheimer's disease with cerebrovascular disease) according to the NIAAA criteria Note: 1. NINDS-AIREN: National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences 2. NIAAA: National Institute on Aging-Alzheimer's Association 3. With mild-to-moderate dementia (score of the Mini-Mental State Examination (MMSE) defined as between 10 to 24) 4. Able to read, write, communicate, and understand cognitive testing instructions 5. Having a responsible caregiver who spends adequate time daily with the patient; the caregiver will accompany the patient to all clinic visits during the study and supervise all study dosing requirements and concomitant medications 6. Signed, by patients and the responsible caregiver, the written informed consent form Exclusion Criteria: 1. With large-artery stroke (thrombotic stroke) 2. With radiological evidence of other brain disorders (subdural hematoma, post-traumatic / post-surgery) 3. With dementia caused by other brain diseases except Alzheimer's disease and vascular dementia (e.g. Parkinson's disease, demyelinated disease of the central nervous system, tumor, hydrocephalus, head injury, central nervous system infection including syphilis, acquired immune deficiency syndrome, etc.) 4. With clinical evidence of pulmonary, hepatic, gastrointestinal, metabolic, endocrine or other life threatening diseases judged by investigators not suitable to enter the study 5. With clinically unstable hypertension, diabetes mellitus, and cardiac disease for the last 3 months 6. With history of stroke and hospitalized for stroke in the previous 3 months 7. With history of alcohol or drug abuse 8. With one of the following abnormal laboratory parameters: hemoglobin \< 10 mg/dL or platelet \< 100\*109/L; creatinine or total bilirubin more than 1.5 times the upper limit value; alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphates (ALP), or γ-glutamyl transferase (γ-GT) more than 2 times the upper limit of normal 9. With depression, not well-controlled with medications. 10. With any uncontrolled illness judged by the investigator that entering the trial may be detrimental to the patient 11. With known or suspected hypersensitivity to any ingredients of study product and vehicle 12. Pregnant or lactating or premenopausal with childbearing potential but not taking reliable contraceptive method(s) during the study period 13. Enrollment in any investigational drug trial within 4 weeks before entering this study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Randomized, delayed start, double blind, parallel group, placebo controlled, multicenter study of piromelatine 20 mg in participants with mild dementia due to Alzheimer's disease
- Could brain stimulation help Alzheimer's patients think more clearly?
- Could a common blood pressure pill recharge brain cells in Alzheimer's?
- Could an HIV drug tame Alzheimer's? a trial puts it to the test
- Could a breath test reveal Parkinson's risk?
- Can a new pill slow Alzheimer's decline?